Latest News

The ASCO/CCO guidelines recommend brachytherapy (BT) boost for eligible intermediate- (IR) or high-risk (HR) prostate cancer (PCa) patients. We present efficacy, toxicity and quality-of-life (QoL) outcomes in patients treated on a prospective protocol of MRI dose-painted high-dose-rate BT boost(HDR-BT) followed by 5-fraction pelvic radiotherapy(RT) and 6-18 months of androgen deprivation therapy(ADT).

Alicia Morgans: Hi, my name is Alicia Morgans and I am a GU Medical Oncologist and an Associate Professor of Medicine at Northwestern University. I’m so excited to be speaking today with Dr. Philip Kantoff, a Professor of Medicine and a GU Medical Oncologist at Memorial Sloan Kettering, and Anthony D’Amico, who is a Professor […]

(UroToday.com)  Previous studies have shown that a pathological complete response is achieved in ~30-40% of patients with cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer and is associated with favorable outcomes. Unfortunately, pathological staging is only determined after the bladder is already removed. Transurethral resection of bladder tumor (TURBT) plus systemic therapy has been known for decades to […]

(UroToday.com) Dysregulated metabolism is a hallmark of renal cell carcinoma (RCC), driven by overexpression of glutaminase, a key enzyme of glutamine metabolism. Telaglenastat is an investigational, first-in-class, selective, oral glutaminase inhibitor that blocks glutamine utilization and is critical downstream pathways. Pre-clinically, telaglenastat synergized with cabozantinib, a VEGFR2/MET/AXL inhibitor, against RCC tumors utilizing dual inhibition of glucose […]

(UroToday.com)  The kidney cancer oral abstract session at the 2021 America Society of Clinical Oncology (ASCO) annual meeting included a discussant presentation by Dr. Andrea Apolo providing her expertise on expanding VEGF blockade combination therapeutic options in advanced renal cell carcinoma. Targeting angiogenesis via VEGF blockade in clear cell RCC has a long history, including […]

Alicia Morgans: Hi, my name is Alicia Morgans. I’m a GU Medical Oncologist and Associate Professor of Medicine at Northwestern University in Chicago. I’m so excited to have here with me today a good friend and colleague, Dr. Oliver Sartor, who is the Medical Director of the Tulane Cancer Center, as well as being a […]

(UroToday.com) The optimal management of patients with complete response after first-line chemotherapy remains unsettled with guidelines recommending either surveillance or retroperitoneal lymph node dissection (RPLND). At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Jennifer King and colleagues presented results of their study assessing long-term outcomes from a large dataset of patients managed with […]

(UroToday.com) Preferential fat accumulation in the visceral compartment (i.e. central adiposity) increases cardiovascular risk in the general population independent of body mass index (BMI):

(UroToday.com) Testicular cancer is the most common malignancy among men aged 20-39 years, and testicular cancer survivors are at high risk for short-term and long-term cisplatin-based chemotherapy side effects. Hearing loss, a common cisplatin toxicity, is permanent and irreversible. Although pure-tone audiometry is the gold standard to evaluate hearing loss, patient-reported outcomes are more practical and […]

(UroToday.com) The poster discussion for testicular cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting included a discussant presentation by Dr. Timothy Gilligan discussing potential factors we can modify to overcome survivorship challenges in testicular cancer.